Merck
Develops enlicitide, an oral macrocyclic peptide PCSK9 inhibitor for high cholesterol.
Share price
$146
Up 69% over 12 monthsWhat analysts expect
Buy
Buy65%
Hold35%
Sell0%
Price target for the next 12 months
$152Up 5.8% compared with the current price
Price now $144Average targetLowest $92.00 to highest $180
27 analysts. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $67B
- Yearly profit
- $3.2B
- Company value
- $359B
Revenue and profit for the last twelve months reported.
Peptides in this book
- EnlicitidePrescription
Recent news
Risk in the news: Barron's reported a Dutch court ruling for Halozyme that blocks subcutaneous Keytruda sales in eight European markets.
Prices are delayed and figures rounded. Not investment advice.